title: Effect of ONO-5334 on bone mineral density and biochemical markers of bone turnover in postmenopausal osteoporosis: 2-year results from the OCEAN study.
abstract: Cathepsin K inhibitors, such as ONO-5334, are being developed for the treatment of postmenopausal osteoporosis. However, their relative effects on bone resorption and formation, and how quickly the effects resolve after treatment cessation, are uncertain. The aim of this study was to examine the efficacy and safety of 24-month treatment with ONO-5334 and to assess the effect of treatment cessation over 2 months. We studied 197 postmenopausal women with osteoporosis or osteopenia with one fragility fracture. Patients were randomized to ONO-5334 50 mg twice daily, 100 mg or 300 mg once daily, alendronate 70 mg once weekly (positive control), or placebo for 24 months. After 24 months, all ONO-5334 doses were associated with increased bone mineral density (BMD) for lumbar spine, total hip, and femoral neck (p < 0.001). ONO-5334 300 mg significantly suppressed the bone-resorption markers urinary (u) NTX and serum and uCTX-I throughout 24 months of treatment and to a similar extent as alendronate; other resorption marker levels remained similar to placebo (fDPD for ONO-5334 300 mg qd) or were increased (ICTP, TRAP5b, all ONO-5334 doses). Levels of B-ALP and PINP were suppressed in all groups (including placebo) for approximately 6 months but then increased for ONO-5334 to close to baseline levels by 12 to 24 months. On treatment cessation, there were increases above baseline in uCTX-I, uNTX, and TRAP5b, and decreases in ICTP and fDPD. There were no clinically relevant safety concerns. Cathepsin K inhibition with ONO-5334 resulted in decreases in most resorption markers over 2 years but did not decrease most bone formation markers. This was associated with an increase in BMD; the effect on biochemical markers was rapidly reversible on treatment cessation.
authors.affiliation: Academic Unit of Bone Metabolism, University of Sheffield, Sheffield, UK.
authors.forename: Richard
authors.initials: R
authors.lastname: Eastell
authors.forename: Shinichi
authors.initials: S
authors.lastname: Nagase
authors.forename: Maria
authors.initials: M
authors.lastname: Small
authors.forename: Steven
authors.initials: S
authors.lastname: Boonen
authors.forename: Tim
authors.initials: T
authors.lastname: Spector
authors.forename: Michiyo
authors.initials: M
authors.lastname: Ohyama
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Kuwayama
authors.forename: Steve
authors.initials: S
authors.lastname: Deacon
mesh_terms: D000368:Aged; D019386:Alendronate / Q000008:administration & dosage; D015415:Biomarkers / Q000097:blood; D015519:Bone Density / Q000187:drug effects*; D050071:Bone Density Conservation Agents / Q000008:administration & dosage; D001862:Bone Resorption / Q000097:blood / Q000188:drug therapy; D056657:Cathepsin K / Q000037:antagonists & inhibitors*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010012:Osteogenesis / Q000187:drug effects*; D015663:Osteoporosis, Postmenopausal / Q000097:blood / Q000188:drug therapy; D053778:Thiazolidines / Q000008:administration & dosage*; D013997:Time Factors
chemical_list: D015415:Biomarkers; D050071:Bone Density Conservation Agents; C560865:ONO-5334; D053778:Thiazolidines; C534130:CTSK protein, human; D056657:Cathepsin K; D019386:Alendronate
keywords: BIOCHEMICAL MARKERS OF BONE TURNOVER; CLINICAL TRIALS; DXA; MENOPAUSE; OSTEOPOROSIS